EAN 2021 | Real-world effectiveness of fremanezumab for migraine prevention
Dimos-Dimitrios Mitsikostas, MD, PhD, National & Kapodistrian University of Athens, Athens, Greece, introduces the upcoming Pan-European Real Life (PEARL) study, assessing the effectiveness of fremanezumab for migraine prevention in patients with chronic or episodic migraine. The 24-month prospective, observational trial will assess the reduction in monthly migraine days, disability scores, adherence, and acute headache medication use. Prof. Mitsikostas highlights the importance of real-world data to provide evidence of the effectiveness of calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies. This interview took place during the European Academy of Neurology 2021 congress.
Disclosures
Prof. Mitsikostas reports the following disclosures:
Research and traveling grants, honoraria and consultation fees from Allergan, Amgen, Biogen, Cefaly, Eli Lily, ElectroCore, Genesis Pharma, Lundbeck, Novartis, Merz, Sanofi, and Teva.
Trials for Cefaly, Eli Lily, ElectroCore, Lundbeck, Novartis, Merz, Sanofi, and Teva.
Associate Editor in the Journal of Headache and Pain.
Co-chair of the Management group of the Headache Scientific Panel at the European Academy of Neurology and President of the Hellenic Headache Society.
